Japan Pharmaceuticals and Medical Devices Agency

被引：0

作者：

Nagai, S. ^{[1
]}

机构：

[1] Univ Tokyo Hosp, Translat Res Ctr, Tokyo, Japan

来源：

关键词：

conditional approval; MHLW; PMDA;

D O I：

10.1016/j.jtho.2019.08.112

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ES10.02

引用

页码：S38 / S38

页数：1

共 4 条

[1] Lyerly H Kim, 2018, J Glob Oncol, V4, P1, DOI 10.1200/JGO.18.00092
[2] Regulatory approval pathways for anticancer drugs in Japan, the EU and the US
Nagai, Sumimasa
Ozawa, Keiya
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (01) : 73 - 84
[3] Evolving Japanese regulations on companion diagnostics
Nagai, Sumimasa
Urata, Masaaki
Sato, Hiroyuki
Mikami, Motoki
Kuga, Wataru
Yanagihara, Reiko
Miyamoto, Daisei
Suzuki, Yuka
Shikano, Mayumi
[J]. NATURE BIOTECHNOLOGY, 2016, 34 (02) : 141 - 144
[4] Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology
Salgado, Roberto
Solit, David B.
Rimm, David L.
Bogaerts, Jan
Canetta, Renzo
Lively, Tracy
Lyerly, Kim
Span, Paul N.
Bateman-House, Alison
Makady, Amr
Bergmann, L.
Nagai, Sumimasa
Smith, Chris
Robson, Mark
Savage, Mary
Voest, Emile
Sweeney, Christopher
Lambin, Philippe
Thomas, Marlene
Harris, Lyndsay
Lacombe, Denis
Massard, Chistophe
Lyerly, Herbert K.
Yee, Laura
Rimm, David
Bateman-Houseaj, Alison
Bergmann, Lothar
Nagaiam, Sumimasa
Thomasan, Marlene
Cree, Ian A.
Hopper, Shirley
Robson, Marc
Ingelman-Sundberg, Magnus
Maignen, Francois
Besse, Benjamin
Swierzewski, Rafal
Kiermaier, Astrid
Lacombex, Denis
Livelyad, Tracy
Massard, Christophe
Salgadobf, Roberto
Golfinopoulos, Vassilis
[J]. EUROPEAN JOURNAL OF CANCER, 2019, 114 : 128 - 136